205 related articles for article (PubMed ID: 30362063)
1. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort.
Pietrasz D; Turrini O; Vendrely V; Simon JM; Hentic O; Coriat R; Portales F; Le Roy B; Taieb J; Regenet N; Goere D; Artru P; Vaillant JC; Huguet F; Laurent C; Sauvanet A; Delpero JR; Bachet JB; Sa Cunha A
Ann Surg Oncol; 2019 Jan; 26(1):109-117. PubMed ID: 30362063
[TBL] [Abstract][Full Text] [Related]
2. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
Pietrasz D; Marthey L; Wagner M; Blanc JF; Laurent C; Turrini O; Raoul JL; Terrebonne E; Hentic O; Trouilloud I; Coriat R; Regenet N; Innominato P; Taieb J; Cunha AS; Bachet JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1196-205. PubMed ID: 26271395
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
4. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
[TBL] [Abstract][Full Text] [Related]
5. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
[TBL] [Abstract][Full Text] [Related]
6. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Kourie H; Auclin E; Cunha AS; Gaujoux S; Bruzzi M; Sauvanet A; Lourenco N; Trouilloud I; Louafi S; El-Hajjar A; Vaillant JC; Smith D; Touchefeu Y; Bachet JB; Pietrasz D; Taieb J
Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):663-668. PubMed ID: 31029644
[TBL] [Abstract][Full Text] [Related]
7. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
[TBL] [Abstract][Full Text] [Related]
8. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.
Auclin E; Marthey L; Abdallah R; Mas L; Francois E; Saint A; Cunha AS; Vienot A; Lecomte T; Hautefeuille V; de La Fouchardière C; Sarabi M; Ksontini F; Forestier J; Coriat R; Fabiano E; Leroy F; Williet N; Bachet JB; Tougeron D; Taieb J
Br J Cancer; 2021 Jun; 124(12):1941-1948. PubMed ID: 33772154
[TBL] [Abstract][Full Text] [Related]
9. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiotherapy after curative surgery for locally advanced pancreatic cancer: A 20-year single center experience.
Weibel P; Pavic M; Lombriser N; Gutknecht S; Weber M
Surg Oncol; 2021 Mar; 36():36-41. PubMed ID: 33285435
[TBL] [Abstract][Full Text] [Related]
11. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
14. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.
Ge X; Zhao Q; Song Y; Li J; Liu M; Bai W; Qiao X
Eur J Surg Oncol; 2018 Apr; 44(4):502-508. PubMed ID: 29395438
[TBL] [Abstract][Full Text] [Related]
15. Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma.
Duconseil P; Garnier J; Weets V; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Poizat F; Giovannini M; Delpero JR; Turrini O
World J Surg Oncol; 2019 Jun; 17(1):95. PubMed ID: 31164144
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.
Mokdad AA; Minter RM; Yopp AC; Porembka MR; Wang SC; Zhu H; Augustine MM; Mansour JC; Choti MA; Polanco PM
J Natl Compr Canc Netw; 2018 Dec; 16(12):1468-1475. PubMed ID: 30545994
[No Abstract] [Full Text] [Related]
17. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
18. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
Malaisrie SC; Hofstetter WL; Correa AM; Ajani JA; Komaki RR; Rice DC; Vaporciyan AA; Walsh GL; Roth JA; Wu TT; Swisher SG
Cancer; 2006 Sep; 107(5):967-74. PubMed ID: 16874819
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer.
Sakr A; Elsherbiny M; Abdel Moneim R; Shaaban S; Aldaly M
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1717-1723. PubMed ID: 32592369
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
